Neutrophilic dermatosis complicating lenalidomide therapy.
Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent introduced in 2004 for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of myelodysplastic syndrome and is currently under investigative use for metastatic melanoma. We present a case of neutrophilic dermatosis involving predominantly the lower extremities in a patient receiving lenalidomide therapy for multiple myeloma.
Thieu
Khanh P
KP
Harvard Medical School, Boston, Massachusetts, USA.
Rosenbach
Misha
M
Xu
Xiaowei
X
Kist
Joseph M
JM
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012867:Skin / Q000473:pathology; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide